BOPI 08 BR/2023 REPERTOIRE NUMERIQUE 31 (72) DONG, Hanqing (US); DUGUID, Robert J. (US); JAGER, Casey Keith (US); KAUSHAL, Aditya Mohan (US); KENNEDY, Samuel Elliott (US); NEESER, Miranda Annell (US); REEVE, Maxwell Marco (US); REO, Joseph P. (US); ZAHEDI, Mohammad Mehdi (US); KATTUBOINA, Venkata A. (US); ALLAN, Laura E.N. (GB); CHEN, Chungpin Herman (US); GROSSO, John A. (GB); HASKELL, III, Royal J. (US); LLOYD, Rhys (GB); REECE, Hayley (US); ROBERTSON, Jerod (US) et QIU, Yuping (US) (73) ARVINAS OPERATIONS, INC., 5 Science Park, 395 Winchester Avenue, NEW HAVEN, Connecticut 06511 (US) (74) S.C.P AKKUM, AKKUM & Associates, n° 1777, Rue 6.261, Auditorium Jean Paul II, Quartier Mbankolo, B.P. 4966, YAOUNDE (CM). (57) The present disclosure relates to ultra-pure forms, polymorphs, amorphous forms, and formulations of N-[(1r,4r)-4-(3-chloro-4cyanophenoxy)cyclohexyl]-6-[4-({4-[2-(2,6dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro1H-isoindol-5-yl]piperazin-1-yl}methyl)piperidin-1yl]pyridazine-3-carboxamide, referred to herein as Compound A : Fig. 1 & (Compound A).
RkJQdWJsaXNoZXIy MTM1NDc3MA==